Minimal residual disease (MRD) monitoring by quantitative RT-PCR (RQ PCR) and FISH in chronic myelogenous leukemia (CML) patients treated with STI571 (Gleevec®).

被引：0
|
作者：
Roche, C
Grardel, N
Cornu-Soenen, V
Laï, JL
Roumier, C
Berthaud, P
Chatelain, N
Cosson, A
Facon, T
Preudhomme, C
机构：
[1] INSERM, CHU Lille, U524, Lab Hematol A, F-59045 Lille, France
[2] INSERM, CHU Lille, U524, Lab Cytogenet, F-59045 Lille, France
[3] INSERM, CHU Lille, Lab Hematol A, F-59045 Lille, France
[4] Novartis France, Div Oncol, Paris, France
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2578
引用
收藏
页码：615A / 615A
页数：1
相关论文
共 50 条
  • [1] Minimal residual disease (MRD) monitoring in chronic myelogenous leukemia (CML) patients treated with STI571 (Glivec®)
    Roche-Lestienne, C
    Grardel-Duflos, N
    Cornu-Soenen, V
    Laï, JL
    Roumier, C
    Berthaud, P
    Cosson, A
    Facon, T
    Preudhomme, C
    LEUKEMIA, 2001, 15 (12) : 2023 - 2023
  • [2] Real-time quantitative RT-PCR monitoring of tyrosine kinase inhibitor (STI571/imatinib) treated chronic myelogenous leukemia patients.
    Bories, D
    Chami, I
    Perot, C
    Vandenakker, J
    Yacouben, K
    Geraudier, S
    Pautas, C
    Kuentz, M
    Cordonnier, C
    Berthaud, P
    Tulliez, M
    BLOOD, 2001, 98 (11) : 615A - 616A
  • [3] Monitoring the response of CML patients treated with STI571 by molecular cytogenetics and quantitative RT-PCR.
    Paschka, P
    Schoch, C
    Lahaye, T
    Weisser, A
    Kuhn, C
    La Rosée, P
    Kreil, S
    Berger, U
    Haferlach, T
    Gschaidmeier, H
    Hehlmann, R
    Hochhaus, A
    BLOOD, 2000, 96 (11) : 734A - 734A
  • [4] Monitoring minimal residual disease by BCR-ABL Western and quantitative competitive RT PCR in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) on STI571 therapy.
    Quackenbush, RC
    Talpaz, M
    Guo, JQ
    Arlinghaus, RB
    Resta, D
    Capdeville, R
    Rios, MB
    Giles, FJ
    Kantarjian, HM
    BLOOD, 2000, 96 (11) : 736A - 736A
  • [5] Conventional cytogenetic and quantitative RT-PCR (RQ-PCR) follow-up of chronic myelogenous leukemia (CML) patients treated by imatinib.
    Darre, S
    Roche-Lestienne, C
    Lai, JL
    Facon, T
    Roumier, C
    Berthaud, P
    Guilhot, J
    Preudhomme, C
    BLOOD, 2003, 102 (11) : 417A - 417A
  • [6] MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN CML PATIENTS: COMPARISON BETWEEN AUTOMATED FISH ANALYSIS AND RQ-PCR
    Calabrese, G.
    Fantasia, D.
    Pompetti, E.
    Di Gianfilippo, R.
    Guanciali-Franchi, P.
    Romagno, D.
    Morizio, E.
    Alfonsi, M.
    Pulini, S.
    Spadano, A.
    Di Lorenzo, R.
    Di Bartolomeo, P.
    Iacone, A.
    Palka, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 230 - 230
  • [7] Minimal residual disease (MRD) monitoring with qualitative RT-PCR in chronic myeloid leukemia (CML) patients submitted to allogeneic stem cell transplantation
    Bernasconi, P
    Alessandrino, EP
    Calatroni, S
    Caldera, D
    Colombo, AA
    Malcovati, L
    Varettoni, M
    Cavigliano, PM
    Rocca, B
    Boni, M
    Giardini, I
    Caresana, M
    Lazzarino, M
    BONE MARROW TRANSPLANTATION, 2002, 29 : S123 - S123
  • [8] SIGNIFICANCE OF RT-PCR AND FISH AS MINIMAL RESIDUAL DISEASE (MRD) IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA (AL)
    Aguilar, Rocio Yemeli Buenrostro
    Cabrera, Daniela Arce
    Guzman, Jorge
    Altamirano, Eduardo
    Lozano, Jose Rodrigo
    Aguilar, Guadalupe Valenzuela
    Guzman, Obdilia Gutierrez
    Echeverria, Maite
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S575 - S575
  • [9] Pharmacogenetic analysis of cytogenetic response in chronic myelogenous leukemia patients treated with imatinib (Glivec®/Gleevec™, STI571).
    Malinowski, RH
    Dressman, M
    McLean, LA
    Gathmann, I
    Capdeville, R
    BLOOD, 2002, 100 (11) : 547A - 547A
  • [10] Quantitative RT-PCR using minor groove binder (MGB) probes demonstrates that Gleevec can induce minimal residual disease states and molecular remissions in a subset of patients with chronic myelogenous leukemia (CML).
    Shah, NP
    Nicoll, JM
    Wang, JQ
    Snyder, DS
    McMahon, RJ
    Paquette, RL
    Forman, SJ
    Radich, JP
    Kummer, N
    Ford, J
    Kutyavin, IV
    Patnaik, M
    Sawyers, CL
    BLOOD, 2001, 98 (11) : 613A - 613A
12345